Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weightloss. The drug received approval from Chinese regulators last year. In February last year, Lilly CEO David Ricks told Reuters that it expects to launch Moun jaro, in India as early as next year. \”The size is significant. We’re talking about 900 million patients that could benefit from Moun Jaro,\” said Lilly’s Lucas Montarce at the Leerink Partners Global Healthcare Conference. The company’s drug is sold under the brand name Zepbound for obesity in the U.S., but is also known as MounJaro in Europe and the UK, and as Zep bound for diabetes in Australia and New Zealand, and Zep Bound for weightloss in the United States. For confidential support call the Samaritans on 08457 90 90 90, visit a local Samaritans branch or see www.samaritans.org for details. For support in the US, call the National Suicide Prevention Lifeline at 1-800-273-8255 or visit www.suicidepreventionlifeline.org.